Quantcast

Latest Arginine Stories

2011-10-26 13:00:00

Healthhound.org releases their report on Force Factor ingredients and give away a viable alternative to the supplements. Houston, TX. (PRWEB) October 26, 2011 Healthhound.org has released their long awaited report this week on the Force Factor ingredients and if the reaction on the health related blogs is anything to go by, there certainly are many people that have been awaiting for this report with bated breath. Healthhound.org has built a reputation for itself as a leading authority when...

2011-07-28 07:00:00

SAN DIEGO, July 28, 2011 /PRNewswire/ -- Polaris Group (Polaris) today announced that it has dosed the first patient in a pivotal Phase 3 clinical trial evaluating its lead cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in hepatocellular carcinoma (HCC) patients. Over 600 patients who have failed prior systemic therapy will be enrolled in the randomized, double-blind, placebo-controlled study at sites in China, Taiwan, the United States, Italy and the U.K.. Patients will...

2011-06-03 12:19:13

Using a high-resolution single-molecule study technique, University of Illinois researchers have seen the very subtle differences between two branches of an important family of neurotransmitter-gated ion channels. Professor Claudio Grosman and research scientist Gisela Cymes published their work in the journal Nature. Nicotinic-type receptors are proteins embedded in the membranes of nerve and muscle cells that regulate activity. A neurotransmitter, such as acetylcholine, triggers a small...

2011-05-23 07:26:21

(Ivanhoe Newswire) -- A new study shows a dietary supplement containing an amino acid and antioxidant vitamins may protect pregnant women from preeclampsia. Preeclampsia affects about 5 percent of women during their first pregnancy. It's a serious condition where moms-to-be experience high blood pressure and other disturbances. Preeclampsia is dangerous for both the mother and the baby. Some believe preeclampsia may be linked to a deficiency in L-arginine -- an amino acid that helps maintain...

2011-05-20 13:05:32

Research: Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: Randomized controlled trial A dietary supplement containing an amino acid and antioxidant vitamins, given to pregnant women at high risk of pre-eclampsia, can reduce the occurrence of the disease, finds a study published on bmj.com today. Pre-eclampsia is a serious condition where abnormally high blood pressure and other disturbances develop...

2011-05-18 07:00:00

NEW YORK and SAN DIEGO, May 18, 2011 /PRNewswire/ -- Ludwig Institute for Cancer Research LTD (LICR) and Polaris Group (Polaris) today announced the formation of a collaboration to expand development of Polaris' novel cancer drug, pegylated arginine deiminase (ADI-PEG 20). ADI-PEG 20 kills tumor cells by depletion of the amino acid arginine. As part of the collaboration, LICR and Polaris will explore further the potential of ADI-PEG 20 as a cancer therapy and aim to identify other amino...

2011-05-12 07:00:00

SAN DIEGO, May 12, 2011 /PRNewswire/ -- Polaris Group (Polaris) today announced that the Company will highlight clinical development plans for its Phase 3-ready pegylated arginine deiminase, ADI-PEG 20, during a symposium held on Tuesday, May 24, at 1:30 p.m. China Standard Time in Taipei, Taiwan. Details about Polaris' upcoming pivotal Phase 3 clinical trial of ADI-PEG 20 in hepatocellular carcinoma (HCC) will be presented by the principal investigator, Ghassan Abou-Alfa, M.D., of...

2011-04-11 09:13:00

SAN DIEGO, April 11, 2011 /PRNewswire/ -- Polaris Group (Polaris) announced today that data from preclinical studies of ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic, is synergistic with hydroxychloroquine (ChQ) in a human pancreatic cancer cell line and with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in human melanoma cell lines. Both ChQ and TRAIL are known inhibitors of autophagy. These results support the commencement of Phase 1/2 clinical...

2011-04-08 07:00:00

SAN DIEGO, April 8, 2011 /PRNewswire/ -- Polaris Group (Polaris) announced today that data from preclinical studies suggest ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic, may be effective in treating acute myeloid leukemia (AML), glioblastoma multiforme (GBM) and bladder cancer. These cancers have a high incidence of deficiencies of the arginine synthesis enzyme argininosuccinate synthetase (ASS) due to hypermethylation at the promoter of the gene that codes for ASS...

2011-03-31 07:00:00

SAN DIEGO, March 31, 2011 /PRNewswire/ -- Polaris Group (Polaris) today announced that the U.S. Food & Drug Administration (FDA) has approved the company's Special Protocol Assessment (SPA) for a Phase 3 clinical trial of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced hepatocellular carcinoma (HCC). The randomized, placebo-controlled, global trial will enroll approximately 600 patients who have failed prior systemic chemotherapy. The primary endpoint of the study...


Word of the Day
pungle
  • To take pains; labor assiduously with little progress.
This word comes from the Spanish 'pongale,' put it.
Related